No benefit of plasma therapy in reducing COVID-19 mortality risk, says AIIMS trial interim analysis

During the trial, one group of patients was given convalescent plasma therapy along with the standard supportive treatment while the other group only received standard treatment. The number of fatalities recorded in both the groups was equal and there was not much clinical improvement in the condition of patients, AIIMS Director Dr Randeep Guleria said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fzd5uT
via IFTTT